119 related articles for article (PubMed ID: 27196891)
1. Mechanisms of Cell Killing Response from Low Linear Energy Transfer (LET) Radiation Originating from (177)Lu Radioimmunotherapy Targeting Disseminated Intraperitoneal Tumor Xenografts.
Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27196891
[TBL] [Abstract][Full Text] [Related]
2. Sensitization of tumor to ²¹²Pb radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with Rad51.
Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1119-26. PubMed ID: 23200172
[TBL] [Abstract][Full Text] [Related]
3.
Poty S; Mandleywala K; O'Neill E; Knight JC; Cornelissen B; Lewis JS
Theranostics; 2020; 10(13):5802-5814. PubMed ID: 32483420
[No Abstract] [Full Text] [Related]
4. Comparative studies on the therapeutic benefit of targeted α-particle radiation therapy for the treatment of disseminated intraperitoneal disease.
Milenic DE; Baidoo KE; Kim YS; Barkley R; Brechbiel MW
Dalton Trans; 2017 Oct; 46(42):14591-14601. PubMed ID: 28675216
[TBL] [Abstract][Full Text] [Related]
5. Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy.
Garcia-Prada CD; Carmes L; Atis S; Parach A; Bertolet A; Jarlier M; Poty S; Garcia DS; Shin WG; Du Manoir S; Schuemann J; Tillement O; Lux F; Constanzo J; Pouget JP
J Nucl Med; 2023 Dec; 64(12):1956-1964. PubMed ID: 37857502
[TBL] [Abstract][Full Text] [Related]
6. α-Radioimmunotherapy with ²¹³Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma.
Teiluf K; Seidl C; Blechert B; Gaertner FC; Gilbertz KP; Fernandez V; Bassermann F; Endell J; Boxhammer R; Leclair S; Vallon M; Aichler M; Feuchtinger A; Bruchertseifer F; Morgenstern A; Essler M
Oncotarget; 2015 Mar; 6(7):4692-703. PubMed ID: 25576914
[TBL] [Abstract][Full Text] [Related]
7. Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer.
Korsen JA; Gutierrez JA; Tully KM; Carter LM; Samuels ZV; Khitrov S; Poirier JT; Rudin CM; Chen Y; Morris MJ; Bodei L; Pillarsetty N; Lewis JS
Proc Natl Acad Sci U S A; 2022 Jul; 119(27):e2203820119. PubMed ID: 35759660
[TBL] [Abstract][Full Text] [Related]
8. Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting,
Aghevlian S; Cai Z; Hedley D; Winnik MA; Reilly RM
EJNMMI Radiopharm Chem; 2020 Nov; 5(1):22. PubMed ID: 33169241
[TBL] [Abstract][Full Text] [Related]
9. Predictors of long-term outcome from intraperitoneal radioimmunotherapy for ovarian cancer.
Meredith R; You Z; Alvarez R; Partridge E; Grizzle W; LoBuglio A
Cancer Biother Radiopharm; 2012 Feb; 27(1):36-40. PubMed ID: 22239432
[TBL] [Abstract][Full Text] [Related]
10. Towards translation of 212Pb as a clinical therapeutic; getting the lead in!
Yong K; Brechbiel MW
Dalton Trans; 2011 Jun; 40(23):6068-76. PubMed ID: 21380408
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of HER2-Targeted Intraperitoneal
Chung SK; Vargas DB; Chandler CS; Katugampola S; Veach DR; McDevitt MR; Seo SH; Vaughn BA; Rinne SS; Punzalan B; Patel M; Xu H; Guo HF; Zanzonico PB; Monette S; Yang G; Ouerfelli O; Nash GM; Cercek A; Fung EK; Howell RW; Larson SM; Cheal SM; Cheung NV
J Nucl Med; 2023 Sep; 64(9):1439-1445. PubMed ID: 37348919
[TBL] [Abstract][Full Text] [Related]
12. Formulation of patient dose of [
Amirdhanayagam J; Guleria M; Sharma R; Kumar N; Mukherjee A; Das T
J Labelled Comp Radiopharm; 2024 Apr; 67(4):131-144. PubMed ID: 38342496
[TBL] [Abstract][Full Text] [Related]
13. Targeting Breast Cancer Using 177 Lu-Labeled Trastuzumab and Trastuzumab Fragment : First-in-Human Clinical Experience.
Rathore Y; Lakhanpal T; Chakraborty S; Chakravarty R; Mittal BR; Irrinki RNS; Laroiya I; Kaur K; Shukla J
Clin Nucl Med; 2024 Jun; 49(6):e258-e265. PubMed ID: 38579266
[TBL] [Abstract][Full Text] [Related]
14. Initial insights into the interaction of antibodies radiolabeled with Lutetium-177 and Actinium-225 with tumor microenvironment in experimental human and canine osteosarcoma.
Giri S; Allen KJH; Prabaharan CB; Ramirez JB; Fiore L; Uppalapati M; Dadachova E
Nucl Med Biol; 2024 May; 134-135():108917. PubMed ID: 38718557
[TBL] [Abstract][Full Text] [Related]
15. Radiolabelled
Cieslik PA; Klingler S; Nolff M; Holland JP
Chemistry; 2024 Mar; 30(14):e202303805. PubMed ID: 38064536
[TBL] [Abstract][Full Text] [Related]
16. Targeted alpha-therapy: past, present, future?
Brechbiel MW
Dalton Trans; 2007 Nov; (43):4918-28. PubMed ID: 17992276
[TBL] [Abstract][Full Text] [Related]
17. Molecular Radiotherapy with
Huang T; Lee JS; Klibanov AL; He J
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409274
[TBL] [Abstract][Full Text] [Related]
18. Formulation and clinical translation of [
Guleria M; Sharma R; Amirdhanayagam J; Sarma HD; Rangarajan V; Dash A; Das T
RSC Med Chem; 2021 Mar; 12(2):263-277. PubMed ID: 34046615
[TBL] [Abstract][Full Text] [Related]
19. Radioimmunotherapy as a pathogen-agnostic treatment method for opportunistic mucormycosis infections.
Carvalho JLC; Malo ME; Allen KJH; Frank C; Xiao Z; Jiao R; Dadachova E
Access Microbiol; 2023; 5(12):. PubMed ID: 38188245
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory Effects of Radiotherapy.
Kumari S; Mukherjee S; Sinha D; Abdisalaam S; Krishnan S; Asaithamby A
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33142765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
